The Experts below are selected from a list of 21 Experts worldwide ranked by ideXlab platform
Paolo Cravedi - One of the best experts on this subject based on the ideXlab platform.
-
Erythropoietin in Lupus: Unanticipated Immune Modulating Effects of a Kidney Hormone
Frontiers in immunology, 2021Co-Authors: Meghana Eswarappa, Chiara Cantarelli, Paolo CravediAbstract:Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease with variable clinical presentation, typically characterized by a relapsing-remitting course. SLE has a multifactorial pathogenesis including genetic, environmental, and hormonal factors that lead to loss of tolerance against self-antigens and autoantibody production. Mortality in SLE patients remains significantly higher than in the general population, in part because of the limited efficacy of available treatments and the associated toxicities. Therefore, novel targeted therapies are urgently needed to improve the outcomes of affected individuals. Erythropoietin (EPO), a Kidney-produced Hormone that promotes red blood cell production in response to hypoxia, has been shown lately to also possess non-erythropoietic properties, including immunomodulatory effects. In various models of autoimmune diseases, EPO limits cell apoptosis and favors cell clearance, while reducing the proinflammatory cytokines and promoting the induction of regulatory T cells. Notably, EPO has been shown to reduce autoimmune response and decrease disease severity in mouse models of SLE. Herein, we review EPO’s non-erythropoietic effects, with a special focus on immune modulating effects in SLE and its potential clinical utility.
Meghana Eswarappa - One of the best experts on this subject based on the ideXlab platform.
-
Erythropoietin in Lupus: Unanticipated Immune Modulating Effects of a Kidney Hormone
Frontiers in immunology, 2021Co-Authors: Meghana Eswarappa, Chiara Cantarelli, Paolo CravediAbstract:Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease with variable clinical presentation, typically characterized by a relapsing-remitting course. SLE has a multifactorial pathogenesis including genetic, environmental, and hormonal factors that lead to loss of tolerance against self-antigens and autoantibody production. Mortality in SLE patients remains significantly higher than in the general population, in part because of the limited efficacy of available treatments and the associated toxicities. Therefore, novel targeted therapies are urgently needed to improve the outcomes of affected individuals. Erythropoietin (EPO), a Kidney-produced Hormone that promotes red blood cell production in response to hypoxia, has been shown lately to also possess non-erythropoietic properties, including immunomodulatory effects. In various models of autoimmune diseases, EPO limits cell apoptosis and favors cell clearance, while reducing the proinflammatory cytokines and promoting the induction of regulatory T cells. Notably, EPO has been shown to reduce autoimmune response and decrease disease severity in mouse models of SLE. Herein, we review EPO’s non-erythropoietic effects, with a special focus on immune modulating effects in SLE and its potential clinical utility.
Chiara Cantarelli - One of the best experts on this subject based on the ideXlab platform.
-
Erythropoietin in Lupus: Unanticipated Immune Modulating Effects of a Kidney Hormone
Frontiers in immunology, 2021Co-Authors: Meghana Eswarappa, Chiara Cantarelli, Paolo CravediAbstract:Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease with variable clinical presentation, typically characterized by a relapsing-remitting course. SLE has a multifactorial pathogenesis including genetic, environmental, and hormonal factors that lead to loss of tolerance against self-antigens and autoantibody production. Mortality in SLE patients remains significantly higher than in the general population, in part because of the limited efficacy of available treatments and the associated toxicities. Therefore, novel targeted therapies are urgently needed to improve the outcomes of affected individuals. Erythropoietin (EPO), a Kidney-produced Hormone that promotes red blood cell production in response to hypoxia, has been shown lately to also possess non-erythropoietic properties, including immunomodulatory effects. In various models of autoimmune diseases, EPO limits cell apoptosis and favors cell clearance, while reducing the proinflammatory cytokines and promoting the induction of regulatory T cells. Notably, EPO has been shown to reduce autoimmune response and decrease disease severity in mouse models of SLE. Herein, we review EPO’s non-erythropoietic effects, with a special focus on immune modulating effects in SLE and its potential clinical utility.
A. Nagata - One of the best experts on this subject based on the ideXlab platform.
-
Mechanism of action of newly developed vitamin D analogue.
Contributions to nephrology, 1991Co-Authors: Sumiaki Okamoto, E Ejima, T. Kiriyama, M Izumi, A Komori, H Suzuki, T. Katsumata, A. NagataAbstract:26,27-F6-1,25(OH)2D3 has a higher potency both in vivo and in vitro systems, and longer duration of action in vivo, instead of almost equal binding to 1,25(OH)2D3 receptor and comparatively short serum half-life. To date, the mechanism of higher action is not known, but using these analogues as a mirror we might be able to elucidate the mechanism of action or the metabolism of the Kidney Hormone, 1,25(OH)2D3.
Klaus F. Wagner - One of the best experts on this subject based on the ideXlab platform.
-
Expression of the erythropoietin receptor in human heart.
The Journal of thoracic and cardiovascular surgery, 2005Co-Authors: Reinhard Depping, Katsuhiro Kawakami, Hartmut Ocker, Johannes M. Wagner, Matthias Heringlake, Axel Noetzold, Hans-hinrich Sievers, Klaus F. WagnerAbstract:Th Erythropoietin (EPO), the Kidney Hormone regulating erythrocyte production, activates the erythropoietin receptor (EPOR), resulting in antiapoptosis. To investigate the clinical significance of EPOR expressed in neuronal cells of the brain, EPO was administered to patients within 8 hours of the onset of stroke symptoms, which ultimately resulted in the reduction of cerebral infarct size and improvement of functional neurologic performance. Rodents treated with EPO in an animal model of myocardial ischemia and infarction recently demonstrated superior myocardial function. The expression of the EPOR was shown for a variety of rodent and rabbit primary and permanent cardiomyocyte cell lines. But, as noted by several investigators, proof of the presence of the EPOR in the adult human heart is missing. To overcome this deficit, we investigated adult human ventricular and atrial tissue for the expression of the EPOR.
